Treatment of lobar atelectasis with bronchoscopically administered recombinant human deoxyribonuclease in cystic fibrosis?

Clin Respir J. 2008 Apr;2(2):123-6. doi: 10.1111/j.1752-699X.2007.00024.x.


Introduction: Recombinant human deoxyribonuclease (rhDNase) reduces sputum viscosity and improves pulmonary function in cystic fibrosis (CF).

Objective: The objective of this study was to describe our experience in which rhDNase (Pulmozyme; Roche, Basel, Switzerland) was administered by bronchoscopic instillation into atelectatic lobes in five adults with CF.

Conclusion: We found this method successful in treating lobar atelectasis, which was resistant to conventional therapy with antibiotics and physiotherapy. In all but one of the cases we described, administration of DNase in this manner resulted in a radiographic and clinical improvement of the atelectasis. We recommend that respiratory physicians consider this as a second line treatment in the management of atelectasis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bronchoscopy*
  • Cystic Fibrosis / complications
  • Deoxyribonuclease I / administration & dosage*
  • Female
  • Forced Expiratory Volume
  • Humans
  • Instillation, Drug
  • Male
  • Pulmonary Atelectasis / diagnosis
  • Pulmonary Atelectasis / drug therapy*
  • Pulmonary Atelectasis / etiology*
  • Pulmonary Atelectasis / physiopathology
  • Radiography, Thoracic
  • Recombinant Proteins / administration & dosage*
  • Treatment Outcome
  • Young Adult


  • Recombinant Proteins
  • Deoxyribonuclease I